Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Value of Circulating Tumor Cells Isolated by a Novel Microfluidic Platform in Liver Cancer Patients

NCT05242237 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT05242237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05242237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Value of Circulating Tumor Cells Isolated by a Novel Microfluidic Platform in Liver Cancer Patients
Lead sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Observational
Overall status
Unknown status
Start date
December 1, 2021
Completion date
January 31, 2024
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor cell, hepatocellular carcinoma, whole genome sequencing